REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.
In the trial a total of 76 sputum samples were collected from four groups of patients:
1. Healthy individuals that never smoked 2. Heavy smokers with no signs of lung cancer 3. Early stage lung cancer patients (Stage 1) 4. Advanced stage lung cancer patients
The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView’s automated Duet scanning station by Company personnel. The results of the test were classified as “Normal”, i.e. no cancer detected and “Abnormal”, i.e. Cancer detected. These results were then compared to the actual data received from the hospital of the patients’ condition.
The samples included 32 cases of lung cancer patients (about half of them early stage patients) and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two (96.9%) sick patients were correctly diagnosed as “Abnormal” and thirty six of forty four (about 82%) healthy people were correctly diagnosed as “Normal”.
Project leader, Dr. Michal Daniely says:"We have gained great confidence in this test as we see a direct relationship between our results and the clinical status of the patients”.
Dr. Opher Shapira, BioView’s CEO commented: “We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials.”
BioView lung cancer test in based on morphological and genetic analysis of sputum samples and it is running on BioView DUETTM automated scanning platform.
About BioView Ltd.
Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at http://www.bioview.co.il.
Dr. Opher Shapira President and CEO Tel: +972-8-936-6868 Fax: +972-8-936-6869 e-mail: opher@bioview.co.il
Source: BioView Ltd
